Found it in Investor presentation dated 11th Dec 2023. Long term development program repurposing existing oral drugs to intransal delivery. Additional ED products increasing range by dosage and using other PDE5 inhibitors.
Pulmonary Arterial Hypertension- a disorder characterised by high blood pressure in the arteries of the lungs. Scleroderma-Immune disorder attacking healthy tissues,triggering the narrowing of blood vessels. Osteoperosis-thin,weak,fragile bones prone to fracture.
Based on the above I consider the current share price is very reasonable.Not investment advice DYOR.
LTP Price at posting:
$1.82 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)